GGrantIndex
← Leaderboards

Mark Henderson

National Center For Advancing Translational Sciences

$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding mix

By agency

By mechanism

Top collaborators

No co-investigators on record.

Most similar at National Center For Advancing Translational Sciences

Same institution · by research overlap

Others in their field

Top investigators on “Small Molecule

Research focus

Small MoleculeTranslationsHigh Throughput ScreeningNational Center For Advancing Translational SciencesCellsScreeningCollaborationsPharmacologicProgramsRare DiseasesBasic ScienceAutomobile DrivingPharmaceutical ChemistryHuman GenomeDrug CandidateTherapeutic DevelopmentExtramural ActivitiesSmall Molecule TherapeuticsProteinsUnited States National Institutes Of HealthInformaticsBiologyValidationPhenotype

Grant awards (75)

Glucocorticoid-antibody conjugates for selective targeting of immune cells$418,442
ZIA · FY2025 · TR · contact PI
High-throughput screening to identify inhibitors of breast-to-brain metastasis$418,442
ZIA · FY2025 · TR · contact PI
AMPK synthetic activators$348,702
ZIA · FY2025 · TR · contact PI
Screening of natural products for adjuvants that prolong interferon signaling and enhance immune response$278,962
ZIA · FY2025 · TR · contact PI
A cRel bioassay as a predictive model of drug efficacy in a repurposing drug screen for head and neck squamous cell cancers$278,962
ZIA · FY2025 · TR · contact PI
Development of a HT-ATACseq assay to identify epigenetic regulators of Ewing Sarcoma cancer cells (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$278,962
ZIA · FY2025 · TR · contact PI
Identification of small molecules for PI4K2a BRET measurements$278,962
ZIA · FY2025 · TR · contact PI
Targeting MSUT2 binding to polyA mRNA for Alzheimer's disease$278,962
ZIA · FY2025 · TR · contact PI
Identification of inhibitors of the polyamine transporter ATP13A3$278,962
ZIA · FY2025 · TR · contact PI
Identifying LC3 binders to develop lysosome-targeting chimeras$278,962
ZIA · FY2025 · TR · contact PI
Identification of small molecule degraders of XPB for inflammatory diseases$278,962
ZIA · FY2025 · TR · contact PI
Identification of small molecules that improve trafficking of NLGN4X/Y for autism$278,962
ZIA · FY2025 · TR · contact PI
Developing Macrophage Reporter Assays to Assess Immune Cell Responses to Nucleic Acid Therapeutics$278,962
ZIA · FY2025 · TR · contact PI
High-throughput screening to identify modulators of PKD2 function$278,962
ZIA · FY2025 · TR · contact PI
Screening for small molecules that extend the shelf life of blood$278,962
ZIA · FY2025 · TR · contact PI
A Novel Cell-Based Assay to Identify Small Molecules for Galactocerebrosidase (GALC)$209,221
ZIA · FY2025 · TR · contact PI
Modulators of Secreted ER Ca2+ Monitoring Protein (SERCaMP)$209,221
ZIA · FY2025 · TR · contact PI
Development of high-throughput CETSA target engagement assays$139,481
ZIA · FY2025 · TR · contact PI
High-throughput screening to target gliomas$139,481
ZIA · FY2025 · TR · contact PI
Identifying small molecules with selective toxicity towards muscle invasive prostate cancer cells$139,481
ZIA · FY2025 · TR · contact PI
Generation of Tay Sachs cell models and assay approaches for small molecule discovery$69,740
ZIA · FY2025 · TR · contact PI
High-throughput screening to identify inhibitors of breast-to-brain metastasis$491,448
ZIA · FY2024 · TR · contact PI
Evaluation of cAbl allosteric inhibitors in Gaucher-Parkinson$491,448
ZIA · FY2024 · TR · contact PI
AMPK synthetic activators$409,540
ZIA · FY2024 · TR · contact PI
Identification of inhibitors of the polyamine transporter ATP13A3$327,632
ZIA · FY2024 · TR · contact PI
Identifying LC3 binders to develop lysosome-targeting chimeras$327,632
ZIA · FY2024 · TR · contact PI
New approaches for facilitating transcytosis of biologically active molecules$327,632
ZIA · FY2024 · TR · contact PI
Characterizing molecular interactomes using TurboID$327,632
ZIA · FY2024 · TR · contact PI
Identification of small molecule degraders of XPB for inflammatory diseases$327,632
ZIA · FY2024 · TR · contact PI
Identification of small molecules that improve trafficking of NLGN4X/Y for autism$327,632
ZIA · FY2024 · TR · contact PI
High-throughput screening to identify modulators of PKD2 function$327,632
ZIA · FY2024 · TR · contact PI
Development of a HT-ATACseq assay to identify epigenetic regulators of Ewing Sarcoma cancer cells (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$327,632
ZIA · FY2024 · TR · contact PI
Targeting MSUT2 binding to polyA mRNA for Alzheimer's disease$327,632
ZIA · FY2024 · TR · contact PI
Identification of small molecules for PI4K2a BRET measurements$327,632
ZIA · FY2024 · TR · contact PI
A Novel Cell-Based Assay to Identify Small Molecules for Galactocerebrosidase (GALC)$245,724
ZIA · FY2024 · TR · contact PI
Modulators of Secreted ER Ca2+ Monitoring Protein (SERCaMP)$245,724
ZIA · FY2024 · TR · contact PI
Identifying small molecules with selective toxicity towards muscle invasive prostate cancer cells$163,816
ZIA · FY2024 · TR · contact PI
Modulators of Secreted ER Ca2+ Monitoring Protein (SERCaMP)$310,142
ZIA · FY2023 · TR · contact PI
AMPK synthetic activators$240,788
ZIA · FY2023 · TR · contact PI
High-throughput screening to identify modulators of PKD2 function$240,788
ZIA · FY2023 · TR · contact PI
High-throughput screening to identify inhibitors of breast-to-brain metastasis$240,788
ZIA · FY2023 · TR · contact PI
Development of a HT-ATACseq assay to identify epigenetic regulators of Ewing Sarcoma cancer cells (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$125,849
ZIA · FY2023 · TR · contact PI
Evaluation of cAbl allosteric inhibitors in Gaucher-Parkinson$125,849
ZIA · FY2023 · TR · contact PI
Identification of small molecule degraders of XPB for inflammatory diseases$125,849
ZIA · FY2023 · TR · contact PI
Identification of small molecules that improve trafficking of NLGN4X/Y for autism$125,849
ZIA · FY2023 · TR · contact PI
Identifying small molecules with selective toxicity towards muscle invasive prostate cancer cells$125,849
ZIA · FY2023 · TR · contact PI
Identifying LC3 binders to develop lysosome-targeting chimeras$125,849
ZIA · FY2023 · TR · contact PI
New approaches for facilitating transcytosis of biologically active molecules$125,849
ZIA · FY2023 · TR · contact PI
Characterizing molecular interactomes using TurboID$125,849
ZIA · FY2023 · TR · contact PI
A Novel Cell-Based Assay to Identify Small Molecules for Galactocerebrosidase (GALC)$98,849
ZIA · FY2023 · TR · contact PI
Clinical development of emetine hydrochloride for the treatment of viral infection$945,175
ZIA · FY2022 · TR · contact PI
AMPK synthetic activators$259,560
ZIA · FY2022 · TR · contact PI
High-throughput screening to identify inhibitors of breast-to-brain metastasis$259,560
ZIA · FY2022 · TR · contact PI
High-throughput screening to identify modulators of PKD2 function$259,560
ZIA · FY2022 · TR · contact PI
A Novel Cell-Based Assay to Identify Small Molecules for Galactocerebrosidase (GALC)$146,225
ZIA · FY2022 · TR · contact PI
New approaches for facilitating transcytosis of biologically active molecules$146,225
ZIA · FY2022 · TR · contact PI
Characterizing molecular interactomes using TurboID$146,225
ZIA · FY2022 · TR · contact PI
Identifying Irg1 inhibitors to modulate macrophage function$146,225
ZIA · FY2022 · TR · contact PI
Identification of small molecule degraders of XPB for inflammatory diseases$146,225
ZIA · FY2022 · TR · contact PI
Identification of small molecules that improve trafficking of NLGN4X/Y for autism$146,225
ZIA · FY2022 · TR · contact PI
Identifying small molecules with selective toxicity towards muscle invasive prostate cancer cells$146,225
ZIA · FY2022 · TR · contact PI
Development of a HT-ATACseq assay to identify epigenetic regulators of Ewing Sarcoma cancer cells (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)$146,225
ZIA · FY2022 · TR · contact PI
Evaluation of CD206 agonists in diabetic retinopathy$146,225
ZIA · FY2022 · TR · contact PI
Evaluation of cAbl allosteric inhibitors in Gaucher-Parkinson$146,225
ZIA · FY2022 · TR · contact PI
Emetine for SARS-CoV-2$737,750
ZIA · FY2021 · TR · contact PI
High-throughput screening to identify modulators of PKD2 function$201,957
ZIA · FY2021 · TR · contact PI
AMPK synthetic activators$201,957
ZIA · FY2021 · TR · contact PI
High-throughput screening to identify inhibitors of breast-to-brain metastasis$201,957
ZIA · FY2021 · TR · contact PI
NMR characterization of binding of allosteric cAbl inhibitors$121,256
ZIA · FY2021 · TR · contact PI
Evaluation of cAbl allosteric inhibitors in Gaucher-Parkinson$121,256
ZIA · FY2021 · TR · contact PI
Evaluation of cAbl allosteric inhibitors in brain cancer$121,256
ZIA · FY2021 · TR · contact PI
Emetine for SARS-CoV-2$725,728
ZIA · FY2020 · TR · contact PI
High-throughput screening to identify inhibitors of breast-to-brain metastasis$112,360
ZIA · FY2020 · TR · contact PI
AMPK synthetic activators$112,360
ZIA · FY2020 · TR · contact PI
High-throughput screening to identify modulators of PKD2 function$112,360
ZIA · FY2020 · TR · contact PI